which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease. By Teddy Rosenbluth Cassava Sciences, a small ...

This is unnecessary pain and suffering that could be avoided if we were simply allowed to keep patients on the FDA-approved medication that was appropriate in the first place. Alzheimer’s ...

Cassava Sciences' Alzheimer's drug simufilam failed to meet primary ... subset could be put forward that would persuade the FDA simufilam deserves another shot at proving itself?

NEW TONIGHT AT 11 TRIBE CLINICAL RESEARCH IN GREENVILLE HAS LAUNCHED A NEW TRIAL FOR A DRUG CENTERED ON ALZHEIMER’S PREVENTION ... LEADS THE DRUGS TO FDA APPROVAL. TCR NORMALLY SEES PATIENTS ...

In experiments performed on genetically modified mice replicating Alzheimer's disorder, researchers turned off zDHHC enzymes using an experimental nasal-spray drug called "2-bromopalmitate." ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...